19 June 2013
Keywords: further, pollinex, quattro, data, allergy, therapeutics, uk-based
Article | 16 June 2008
UK-based company Allergy Therapeutics has announced further results from the G301 Phase III trial of Pollinex Quattro Grass annual injection
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 June 2008
© 2013 thepharmaletter.com